Tagworks Pharmaceuticals

What Tagworks Pharmaceuticals does

Tagworks Pharmaceuticals is a privately held, clinical-stage precision oncology company founded in 2011 and headquartered in Nijmegen, The Netherlands, with US operations in the Boston area. The company is built around its proprietary Click-to-Release platform, a bioorthogonal chemistry technology based on the pyridazine elimination reaction that enables controlled, in vivo drug release through sequential administration of a trans-cyclooctene (TCO)-linked payload and a tetrazine trigger. The platform is applied to two first-in-class clinical programs: TGW101, a click-cleavable antibody-drug conjugate (ADC) targeting TAG-72 with a monomethyl auristatin E (MMAE) payload, currently in a US Phase 1 dose-escalation trial (up to 50 patients with advanced solid tumors, FDA IND cleared April 2025); and TGW211, a HER2-directed radioimmunoconjugate built on trastuzumab, in an investigator-initiated Phase 0/1 trial (CleavHER) sponsored by Radboud University Medical Center in the Netherlands (CTA authorized October 2025). The platform's core technical claim is that it is the only bioorthogonal cleavage reaction selective and fast enough for clinical in vivo use, enabling targeting of non-internalizing receptors and off-target deactivation of circulating radiopharmaceuticals—capabilities conventional ADCs lack.

The company is pre-revenue with no approved products and no commercial pricing; therapeutics are investigational and accessible only through clinical trial participation. Its go-to-market model is therefore a clinical development and regulatory pathway: demonstrating safety and efficacy in well-defined solid tumor indications with the intent of eventual regulatory approval, commercialization (likely via specialty oncology distribution), or partnership/licensing with larger biopharma. Tagworks earns no recurring revenue today and is funded primarily through equity capital, having closed a $65 million Series A in June 2023 led by Ysios Capital and Gilde Healthcare with participation from Novartis Venture Fund, New Enterprise Associates, and Lightstone Ventures. The company is led by a senior team with deep biotech operating experience—CEO Ken Mills (founding CEO of REGENXBIO), CMO Keith Orford (ex-Merck/GSK oncology), Chairman Chris Martin (former CEO of ADC Therapeutics and co-founder of Spirogen)—and is governed by a board comprising representatives from all five lead investors.

Name

Tagworks Pharmaceuticals

Legal name

Tagworks Pharmaceuticals BV

Website

https://tagworkspharma.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Tagworks Pharmaceuticals is a clinical-stage precision oncology company developing first-in-class ADCs and radioimmunoconjugates using its proprietary Click-to-Release bioorthogonal chemistry platform. It serves solid-tumor patients via two clinical programs, TGW101 and TGW211, and is pre-revenue.

Ownership category

akta.pro rank

Product category

Precision Oncology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• Precision oncology therapeutics
• Antibody-drug conjugates
• Click chemistry therapeutics
• Radioimmunoconjugates
• Bioorthogonal drug release

Headquarters

HQ city

Nijmegen

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Therapeutic Development and Commercialization: Pre-revenue clinical stage company developing novel cancer therapeutics. Revenue will come from commercialization of approved drug products following successful clinical development and regulatory approval. Primary focus on ADC and radiopharmaceutical programs for solid tumors.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Tagworks Pharmaceuticals develops clinical-stage precision oncology therapeutics using its proprietary Click-to-Release platform — an in vivo bioorthogonal chemistry technology based on the pyridazine elimination reaction that enables controlled drug release in the tumor microenvironment. The company is advancing two lead clinical programs: TGW101, a click-cleavable antibody-drug conjugate targeting TAG-72 for advanced solid tumors (Phase 1), and TGW211, a HER2-directed radioimmunoconjugate for HER2-positive tumors (Phase 0/1).

Product overview

Tagworks Pharmaceuticals is a clinical-stage precision oncology company built around its proprietary Click-to-Release platform technology. The platform enables controlled drug release through in vivo bioorthogonal click chemistry, using sequential administration of TCO-linked payloads and tetrazine triggers. The company applies this technology across two lead clinical programs: TGW101, a click-cleavable ADC targeting TAG-72 for solid tumors; and TGW211, a HER2-directed radioimmunoconjugate for targeted radiotherapy. The platform addresses limitations of conventional ADCs by enabling targeting of non-internalizing receptors and improving therapeutic index through chemically controlled activation.

Differentiator

Problem solved

Functional benefit

Products and services

• TGW101 TGW101 is a first-in-class antibody-drug conjugate (ADC) targeting tumor-associated glycoprotein 72 (TAG-72) with monomethyl auristatin E (MMAE) payload, using a TAG72-binding diabody conjugated with a TCO-linked MMAE linker. It uses Tagworks' Click-to-Release linker chemistry to enable controlled drug release in the tumor microenvironment without requiring target internalization, and is in Phase 1 clinical trials for patients with advanced solid tumors.
• TGW211 TGW211 is a first-in-class HER2-directed radioimmunoconjugate developed with Tagworks' Click-to-Release platform, using trastuzumab linked via a click-cleavable linker for targeted radiotherapy with selective and rapid elimination of undesired circulating radioactivity through trigger-mediated clearance. It is being evaluated in the Phase 0/1 CleavHER trial for HER2-positive tumors.

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered core partnership, research collaboration and research consortium.

• Radboud University Medical Centercore partnershipStrategic or Co-development Partner · 15 October 2025Investigator-initiated trial agreement for Phase 0/1 CleavHER clinical trial of TGW211. Prof. James Nagarajah, MD is Principal Investigator at Radboudumc. Trial evaluating safety, pharmacokinetics, and dosimetry of TGW211 in HER2-positive solid tumors.
• City of Hope Beckman Research Instituteresearch collaborationStrategic or Co-development Partner · 1 January 2015Collaboration with professor Paul Yazaki's research group on click chemistry-triggered activation of ADCs. Awarded US$465,000 Breakthrough Award from US Department of Defense Breast Cancer Research Program in 2015.
• EU Horizon2020 Click-It Consortiumresearch consortiumStrategic or Co-development Partner · 1 January 2015Five-partner consortium secured €6 million EU Horizon2020 grant for In Vivo Click PET Imaging Agents project. Partners include University of Copenhagen (coordinator), Technical University of Vienna, Austrian Institute of Technology, and Johannes Gutenberg University Mainz.
• University of Missouri-Columbiaresearch collaborationStrategic or Co-development Partner · 1 January 2013Collaboration with prof. Tom Quinn on NIH grant for in vivo metal-free cycloaddition chemistry driven pretargeted cancer radiotherapy. Awarded $585k Exploratory/Development grant from NIH IMAT program, ranked in top 9% of applications.
• Avipepresearch collaborationStrategic or Co-development PartnerCollaboration on pretargeting using click chemistry in vivo published in Journal of Nuclear Medicine. Australian biotech company specializing in pretargeting approaches for radioimmunotherapy.
• SyMO-Chemresearch collaborationStrategic or Co-development PartnerCollaboration partner in Nature Communications publication on click-cleavable ADC. Dutch chemistry company specializing in contract research for pharmaceutical and biotech industries.
• Syncomresearch collaborationStrategic or Co-development PartnerCollaboration partner in Nature Communications publication on click-cleavable ADC. Dutch contract research organization focused on organic chemistry and medicinal chemistry.
• Levenaresearch collaborationStrategic or Co-development PartnerCollaboration partner in Nature Communications publication on click-cleavable ADC. Company involved in ADC linker chemistry development.
• Radboud University & Medical Centerresearch collaborationStrategic or Co-development PartnerAcademic collaboration partner in Nature Communications publication demonstrating therapeutic proof of concept. Provided research capabilities for preclinical ADC development.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• ADC Therapeutics: Clinical and commercial-stage ADC company developing oncology therapeutics. Tagworks' chairman Chris Martin was ADC Therapeutics' founding CEO and led Zynlonta to approval, while VP Maria Cincotta drove the Zynlonta clinical operations — making ADC Therapeutics the closest operational and scientific analog for Tagworks' ADC program.

Broad incumbents

• Daiichi Sankyo: Global leader in ADC technology through its DXd platform (Enhertu, Datroway) partnered with AstraZeneca. Sets the standard against which any next-generation ADC platform — including Tagworks' Click-to-Release — must differentiate, and represents the most likely strategic acquirer or partner at clinical proof-of-concept.
• AstraZeneca: Holds commercial rights to Enhertu and Datroway via the Daiichi Sankyo alliance and previously acquired Spirogen (Pyridazine-DXd chemistry lineage). Represents both a competitive incumbent and a logical strategic acquirer for differentiated ADC platform technologies such as Click-to-Release.
• Pfizer: Acquired Seagen for $43B in 2023, gaining a leading ADC franchise including Padcev and Adcetris. Pfizer's large ADC footprint and BD appetite make it both a benchmark and a potential partner or acquirer for Tagworks at clinical proof-of-concept.
• AbbVie (ImmunoGen): Acquired ImmunoGen in 2024 for $10B to gain Elahere, an approved FRα-targeted ADC. Represents another large incumbent with ADC capability and integration capacity for differentiated ADC platforms.
• Lantheus Holdings: Radiopharmaceutical specialist with approved diagnostic and therapeutic radioligand products (e.g., PNT2002, Pylarify). The most direct comparable for TGW211's HER2-directed radioimmunoconjugate program and a potential strategic partner or acquirer in radiopharma.

Emerging players

• Pyxis Oncology: Clinical-stage ADC-focused oncology company with multiple proprietary ADC programs. Comparable to Tagworks in scale, stage, and strategic positioning as a pre-commercial ADC platform play competing for partnership interest.
• Mythic Therapeutics: Emerging ADC developer using novel protein engineering approaches to address ADC limitations such as off-target toxicity. Comparable to Tagworks in targeting the same scientific pain points in conventional ADCs but with a different technical solution.
• ARTBIO: Emerging radiopharmaceutical company developing targeted alpha therapies for solid tumors. Comparable to Tagworks as a clinical-stage precision radiopharma player pursuing novel chemistries for selective tumor delivery.
• Shasqi: Clinical-stage oncology company applying bioorthogonal click chemistry for local tumor activation of systemic therapeutics. The closest mechanistic peer to Tagworks' Click-to-Release platform, providing a reference point for clinical translation of click-chemistry-based oncology approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/tagworks-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tagworks Pharmaceuticals